Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis - 06/08/11
, Sybren Meijer, ProfMD a, Otto S Hoekstra, ProfMD b, Ingid I Riphagen, MSc c, Henrica CW de Vet, ProfPhD d, e, Dirk L Knol, PhD d, e, Nicole CT van Grieken, PhD f, Wilhelmus JHJ Meijerink, PhD aSummary |
Background |
No consensus exists on the validity of the sentinel-lymph-node procedure for assessment of nodal status in patients with colorectal cancer. We aimed to assess the diagnostic performance of this procedure.
Methods |
We searched Embase and PubMed databases for studies published before March 20, 2010. Eligible studies had a prospective design, a sample size of at least 20 patients, and reported the rate of sentinel-lymph-node positivity. Individual patient data were requested for localisation and T-stage stratification. A subset of reports with high methodological quality was selected and analysed.
Findings |
We identified 52 eligible studies, which included 3767 sentinel-lymph-node procedures (2961 [78·6%] colon and 806 [21·4%] rectal carcinomas). Most tumours 2339 (62·1%) were stage T3 or T4. 1887 (50·1%) of patients were male, 1880 (49·9%) female. Mean overall weighted-detection rate was 0·94 (95% CI 0·92–0·95), at a pooled sensitivity of 0·76 (0·72–0·80) with limited heterogeneity (χ2=286·08, degrees of freedom=51; p=0·003). A mean weighted upstaging of 0·15 (95% CI 0·12–0·19) was noted. Individual patient data were available from 19 studies that included 1168 patients. Analysis of these data showed no significant difference in sensitivity between colon (0·86 [95% CI 0·83–0·90]) and rectal cancer (0·82 [0·77–0·88]; p=0·23). Also, there was no dependency of sensitivity on T stage for both colon (pT1: 0·79 [95% CI 0·73–0·84], pT2: 0·76 [0·62–0·90], pT3: 0·73 [0·59–0·87], pT4: 0·73 [0·53–0·93]) and rectal cancer (T1 or T2: 0·81 [0·52–0·94] vs T3 or T4: 0·80 [0·51–0·93]). The subgroup of eight studies with high methodological quality showed a mean detection rate of 0·96 (95% CI 0·90–0·99) for colonic tumours and 0·95 (0·75–0·99) for rectal tumours, and a mean sensitivity of 0·90 (95% CI 0·86–0·93) for colonic tumours and 0·82 (0·60–0·93) for rectal tumours.
Interpretation |
The sentinel-lymph-node procedure shows a low sensitivity, regardless of T stage, localisation, or pathological technique. For every patient diagnosed with colon or rectal cancer without clinical evidence of lymph-node involvement or metastatic disease, this procedure in addition to conventional resection should be considered, since the prognostic information provided by this technique could be clinically significant.
Funding |
Cancer Center Amsterdam Foundation, Amsterdam, Netherlands.
Le texte complet de cet article est disponible en PDF.Plan
Vol 12 - N° 6
P. 540-550 - juin 2011 Retour au numéro
Article précédent
- TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
- Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, Louis Mauriac, Pierre Fumoleau, Etienne Brain, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Khalil Zaman, Tanja Cufer, Alain Lortholary, Elisabet Lidbrink, Sylvie André, Saskia Litière, Lissandra Dal Lago, Véronique Becette, David A Cameron, Jonas Bergh, Richard Iggo, on behalf of the EORTC 10994/BIG 1-00 Study Investigators ‡
- Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort
- Li-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Chao-Sheng Liao, Hsiu-Hsi Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?